ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It focuses on developing a portfolio of its four advanced product candidates, including Pimavanserin, which is in phase III development for Parkinson's disease psychosis; and a product candidate in phase II for chronic pain and a product candidate in phase I for glaucoma, each in collaboration with Allergan, Inc., as well as ACP-106 in IND-track development for neuropsychiatry and sleep indications. Pimavanserin is also in a phase II trial as a co-therapy in schizophrenia and in a proof-of-concept clinical study for sleep maintenance insomnia. ACADIA PharmaceuticalsÂ’ development pipeline also consists of ACP-105 for endocrine indications in IND-track development stage; Serotonin program for neuropsychiatry and sleep indications in preclinical stage; pro-cognitive antipsychotic (PCAP) program for schizophrenia in preclinical stage; Muscarinic program for neuropsychiatry and other indications; and two series of compounds for Parkinson's disease. It has a collaboration agreement with Biovail Laboratories International SRL to co-develop and commercialize pimavanserin in the United States and Canada. The company, formerly known as Receptor Technologies, Inc., was founded in 1993 and is headquartered in San Diego, California.

Key Statistics

Closing Price	1.30
Volume	3.3
Volume Avg	322866
52 Week High	6.60
52 Week Low	1.00
PE	N/A
PE (group average)	78
EPS Year	-0.94
EPS change Q/Q	-0%
EPS change Q/Q Yr ago	-39.47%
EPS change Q/Q next Q est	-15%
EPS change Y/Y	-44.17%
REV change Q/Q	-25%
REV change Q/Q Yr ago	500%
EPS next Q est	-0.20
EPS next Y est	-0.69
Divident Annual	0.00
Dividend Yield	0%